Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc. (CKPT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CKPT · as of Mar 31, 2025
Ownership Breakdown
94
Institutional Holders
▲ 20 vs Q4
$138.18M
Total Inst. Value
▲ $102.71M vs Q4
86.32M
Shares Outstanding
freeFloat 76.99%
34.21M
13F Shares Held
▲ 23.13M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CKPT largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BERYL CAPITAL MANAGEMENT LLC pharmaceutical preparations | 6.07M | 1015.36% | 1015.36% | $24.54B | May 15, 2025 | NEW |
HIGHBRIDGE CAPITAL MANAGEMENT LLC pharmaceutical preparations | 3.83M | 6.41% | 6.41% | $15.48B | May 12, 2025 | NEW |
TORONTO DOMINION BANK pharmaceutical preparations | 3.42M | 5.72% | 5.72% | $13.84B | May 15, 2025 | NEW |
GLAZER CAPITAL, LLC pharmaceutical preparations | 3.17M | 5.29% | 5.29% | $12.79B | May 15, 2025 | NEW |
ODDO BHF ASSET MANAGEMENT SAS pharmaceutical preparations | 2.17M | 3.64% | 3.64% | $8.79B | Jun 5, 2026 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 2.01M | 3.36% | 3.36% | $8.11B | May 9, 2025 | ▲ 110.5K |
BARCLAYS PLC pharmaceutical preparations | 1.29M | 2.16% | 2.16% | $5.23B | Mar 17, 2026 | NEW |
GABELLI FUNDS LLC pharmaceutical preparations | 1.11M | 1.85% | 1.85% | $4.47B | May 14, 2025 | NEW |
GABELLI & CO INVESTMENT ADVISERS, INC. pharmaceutical preparations | 1.02M | 1.70% | 1.70% | $4.12B | May 14, 2025 | NEW |
GROUPE LA FRANCAISE pharmaceutical preparations | 840.0K | 1.40% | 1.40% | $3.39B | May 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
16
Increased
+2.05M shares27
New Positions
first time holders7
Decreased
−525.9K shares0
Sold Out
fully exitedNet shares change (top 50)
+1.53M
+2.05M / −525.9K
Net new holders
+36
27 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CKPT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
8
Buy transactions
10
Sell transactions
0.80
Buy/Sell ratio
$6M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Fortress Biotech, Inc. 10 percent owner | May 29, 2025 | Sale | 100,000 | $1.29 | $129.0K | 6.12M | Form 4 ↗ |
Fortress Biotech, Inc. 10 percent owner | May 30, 2025 | D-Return | 6,122,249 | $4.10 | $25.10M | 0 | Form 4 ↗ |
Fortress Biotech, Inc. 10 percent owner | May 30, 2025 | D-Return | 700,000 | $4.10 | $2.87M | 0 | Form 4 ↗ |
WEISS MICHAEL S director | May 29, 2025 | Award | 50,000 | $1.29 | $64.5K | 187.0K | Form 4 ↗ |
WEISS MICHAEL S director | May 28, 2025 | Award | 12,195 | — | — | 137.0K | Form 4 ↗ |
WEISS MICHAEL S director | May 30, 2025 | U-Tender | 187,007 | $4.10 | $766.7K | 0 | Form 4 ↗ |
SALZMAN BARRY M director | May 28, 2025 | Award | 12,195 | — | — | 147.0K | Form 4 ↗ |
SALZMAN BARRY M director | May 30, 2025 | U-Tender | 147,007 | $4.10 | $602.7K | 0 | Form 4 ↗ |
ROSENWALD LINDSAY A MD director | May 29, 2025 | Award | 50,000 | $1.29 | $64.5K | 207.0K | Form 4 ↗ |
ROSENWALD LINDSAY A MD director | May 28, 2025 | Award | 12,195 | — | — | 157.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Checkpoint Therapeutics, Inc. (CKPT) is primarily owned by institutional investors, who hold approximately 39.6% of total shares outstanding. Company insiders own approximately 23.01%, while retail and public investors account for the remaining 37.35%.
The largest institutional shareholder of Checkpoint Therapeutics, Inc. is BERYL CAPITAL MANAGEMENT LLC, holding approximately 6.07 million shares — equal to 1015.36% of outstanding shares — as of March 31, 2025.
A total of 94 institutional investors currently hold CKPT stock, with a combined institutional value of approximately $138,182,499 as of the most recent 13F filing period.
Frequently asked questions
CKPT ownershipCheckpoint Therapeutics, Inc. (CKPT) is primarily owned by institutional investors, who hold approximately 39.6% of shares. The largest shareholder is BERYL CAPITAL MANAGEMENT LLC with a 1015.36% stake. Company insiders hold 23.01%. Data sourced from SEC Form 13F as of March 31, 2025.